专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070142295A1 Thrombopoietic compounds 审中-公开
标题翻译：血栓形成
公开(公告)号：US20070142295A1
公开(公告)日：2007-06-21
申请号：US11644757
申请日：2006-12-22
申请人： Chuan-Fa Liu , Ulrich Feige , Janet Cheetham
发明人： Chuan-Fa Liu , Ulrich Feige , Janet Cheetham
IPC分类号： A61K38/10 , C07K7/08
CPC分类号： C07K14/524 , A61K38/00 , C07K7/06 , C07K7/08 , C07K2319/00 , C07K2319/30 , C07K2319/75
摘要： The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.
摘要翻译：本发明涉及具有血小板生成活性的化合物，特别是肽或多肽的领域。本发明的肽和多肽可用于增加哺乳动物中的血小板或血小板前体（例如巨核细胞）。

2. 发明授权

US07189827B2 Modified peptides as therapeutic agents 有权
公开(公告)号：US07189827B2
公开(公告)日：2007-03-13
申请号：US10632388
申请日：2003-07-31
申请人： Ulrich Feige
发明人： Ulrich Feige
IPC分类号： C07K5/00
CPC分类号： C12N9/6491 , A61K38/00 , C07K14/505 , C07K14/52 , C07K14/524 , C07K14/525 , C07K14/545 , C07K14/8146 , C07K2319/00 , C07K2319/30
摘要： The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by a process comprising: a) selecting at least one peptide that modulates the activity of a protein of interest; and b) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide is preferably selected by phage display, E. coli display, ribosome display, RNA-peptide screening, or chemical-peptide screening.

3. 发明授权

US07169905B2 Modified peptides as therapeutic agents 失效
公开(公告)号：US07169905B2
公开(公告)日：2007-01-30
申请号：US10651723
申请日：2003-08-29
申请人： Ulrich Feige
发明人： Ulrich Feige
IPC分类号： C07K1/00
CPC分类号： C12N9/6491 , A61K38/00 , C07K14/505 , C07K14/52 , C07K14/524 , C07K14/525 , C07K14/545 , C07K14/8146 , C07K2319/00 , C07K2319/30
摘要： The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by a process comprising: a) selecting at least one peptide that modulates the activity of a protein of interest; and b) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide is preferably selected by phage display, E. coli display, ribosome display, RNA-peptide screening, or chemical-peptide screening.

4. 发明授权

US07166707B2 Modified peptides as therapeutic agents 失效
标题翻译：修饰肽作为治疗剂
公开(公告)号：US07166707B2
公开(公告)日：2007-01-23
申请号：US10609217
申请日：2003-06-27
申请人： Ulrich Feige
发明人： Ulrich Feige
IPC分类号： C07K1/00
CPC分类号： C12N9/6491 , A61K38/00 , C07K14/505 , C07K14/52 , C07K14/524 , C07K14/525 , C07K14/545 , C07K14/8146 , C07K2319/00 , C07K2319/30
摘要： The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by a process comprising: a) selecting at least one peptide that modulates the activity of a protein of interest; and b) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide is preferably selected by phage display, E. coli display, ribosome display, RNA-peptide screening, or chemical-peptide screening.
摘要翻译：本发明涉及Fc结构域与生物活性肽的融合以及使用生物活性肽制备药物的方法。在本发明中，药理活性化合物通过以下方法制备，该方法包括：a）选择至少一种调节目的蛋白质活性的肽; 和b）制备包含与选定肽的至少一个氨基酸共价连接的Fc结构域的药理学试剂。与载体的连接增加了肽的半衰期，否则其将在体内迅速降解。优选的载体是Fc结构域。优选通过噬菌体展示，大肠杆菌展示，核糖体展示，RNA-肽筛选或化学 - 肽筛选来选择肽。

5. 发明申请

US20060189531A1 Thrombopoietic compounds 有权
公开(公告)号：US20060189531A1
公开(公告)日：2006-08-24
申请号：US11335878
申请日：2006-01-19
申请人： Chuan-Fa Liu , Ulrich Feige , Janet Cheetham
发明人： Chuan-Fa Liu , Ulrich Feige , Janet Cheetham
IPC分类号： A61K38/17 , C07K14/47
CPC分类号： C07K14/524 , A61K38/00 , C07K7/06 , C07K7/08 , C07K2319/00 , C07K2319/30 , C07K2319/75
摘要： The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.

6. 发明授权

US5229405A Use of 2-iminothiazolidin-4-one derivatives as novel pharmaceutical active ingredients 失效
标题翻译： 2-IMINOTHIAZOLIDIN-4-ONE衍生物作为新药物活性成分的使用
公开(公告)号：US5229405A
公开(公告)日：1993-07-20
申请号：US866926
申请日：1992-04-10
申请人： Ulrich Feige , Irmgard Wiesenberg , Leo Widler , Pier G. Ferrini , Martin Missbach
发明人： Ulrich Feige , Irmgard Wiesenberg , Leo Widler , Pier G. Ferrini , Martin Missbach
IPC分类号： A61K31/425 , A61K31/426 , A61P29/00 , C07D277/20 , C07D277/38
CPC分类号： A61K31/425
摘要： Compounds of the formula I ##STR1## in which R.sub.1 is lower alk-2-en-1-yl, lower alk-3-en-2-yl, lower alk-2-yn-1-yl or lower alkyl substituted in the 2,3-position by radicals which can be eliminated to give a double bond, R.sub.2 is hydrogen and R.sub.3 is methyl which is unsubstituted or substituted by radicals which can be eliminated together with hydrogen R.sub.2 to give a double bond or R.sub.2 and R.sub.3 are both hydrogen or lower alkyl or are together methylene and R.sub.4 is a group of the formula Ia, Ib or Ic ##STR2## in which R.sub.5 is hydrogen, lower alkyl, lower alk-2-en-1-yl or lower alk-2-yn-1-yl and R.sub.6 is a group of the formula Id or Ie ##STR3## in which R.sub.1, R.sub.2, R.sub.3 and R.sub.5 are as defined, and their pharmaceutically acceptable salts can be used in a novel manner for the treatment of diseases of the rheumatoid type.
摘要翻译：其中R1是低级烷-2-烯-1-基，低级烯-3-烯-2-基，低级烷-2-炔-1-基或低级烷基的式I化合物（I）在2,3位上被可以被去除以产生双键的基团取代，R 2是氢，R 3是未被取代或被可以与氢R 2一起被除去的基团取代的甲基，得到双键或R 2和 R 3是氢或低级烷基或一起是亚甲基，R 4是式Ia，Ib或Ic的基团（Ia）其中R 5是氢，低级烷基（C 1 -C 6），低级烯-2-烯-1-基或低级烷-2-炔-1-基，R6是式Id或Ie（Ide）（Ie）的基团，其中R1，R2 ，R3和R5如上定义，并且其药学上可接受的盐可以以新颖的方式用于治疗类风湿病的疾病。

7. 发明授权

US5177091A Use of carbazones as novel active ingredients in medicaments 失效
标题翻译：使用CARBAZONES作为药物中的新型活性成分
公开(公告)号：US5177091A
公开(公告)日：1993-01-05
申请号：US795210
申请日：1991-11-20
申请人： Ulrich Feige , Irmgard Wiesenberg , Leo Widler , Pier G. Ferrini , Martin Missbach
发明人： Ulrich Feige , Irmgard Wiesenberg , Leo Widler , Pier G. Ferrini , Martin Missbach
IPC分类号： A61K31/425 , A61K31/426 , A61P29/00 , C07D277/20 , C07D277/38
CPC分类号： A61K31/425
摘要： Compounds of formula I ##STR1## wherein X and Y are each independently of the other thio or sulfynyl, R.sub.1 is lower alk-2-en-1-yl, lower alk-3-en-2-yl, lower alk-2--yn-1-yl, or lower alkyl that is substituted in the 2,3-position by radicals that can be eliminated to form a double bond, R.sub.2 is hydrogen and R.sub.3 is unsubstituted methyl or methyl substituted by a radical that can be eliminated together with hydrogen Rhd 2 to form a double bond, or R.sub.2 and R.sub.3 are each hydrogen or lower alkyl or together are methylene, R.sub.4 is free or protected hydroxy, or hydrogen, and R.sub.5 is hydrogen, lower alkyl, lower alk-2-en-1-yl, lower alk-2-yn-1-yl, or lower alkyl that is substituted in the 2,3-position by radicals that can be eliminated to form a double bond, and their pharmaceutically acceptable salts may be used in a novel manner for the treatment of disorders of the rheumatoid type.
摘要翻译：式I的化合物其中X和Y各自独立地为其它硫代或亚硫炔基，R 1为低级烷-2-烯-1-基，低级烯-3-烯-2-基，低级烷基 -2-yn-1-基或在2,3位被可以被去除以形成双键的基团取代的低级烷基，R 2是氢，R 3是未被取代的甲基或被以下基团取代的甲基：可以与氢Rhd 2一起消除以形成双键，或者R 2和R 3各自为氢或低级烷基或一起为亚甲基，R 4为游离或被保护的羟基或氢，R 5为氢，低级烷基，低级烷基， 2-烯-1-基，低级烷-2-炔-1-基或在2,3位被可以被去除以形成双键的自由基取代的低级烷基，及其药学上可接受的盐可以以新颖的方式用于治疗类风湿病的病症。

8. 发明申请

US20120034657A1 THROMBOPOIETIC COMPOUNDS 有权
公开(公告)号：US20120034657A1
公开(公告)日：2012-02-09
申请号：US13278137
申请日：2011-10-20
申请人： Chuan-Fa LIU , Ulrich FEIGE , Janet C. CHEETHAM
发明人： Chuan-Fa LIU , Ulrich FEIGE , Janet C. CHEETHAM
IPC分类号： C12P21/02
CPC分类号： C07K14/524 , A61K38/00 , C07K7/06 , C07K7/08 , C07K2319/00 , C07K2319/30 , C07K2319/75
摘要： The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.

9. 发明授权

US07186810B2 Modified peptides as therapeutic agents 失效
公开(公告)号：US07186810B2
公开(公告)日：2007-03-06
申请号：US10653048
申请日：2003-08-29
申请人： Ulrich Feige
发明人： Ulrich Feige
IPC分类号： C07K1/00
CPC分类号： C12N9/6491 , A61K38/00 , C07K14/505 , C07K14/52 , C07K14/524 , C07K14/525 , C07K14/545 , C07K14/8146 , C07K2319/00 , C07K2319/30
摘要： The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by a process comprising: a) selecting at least one peptide that modulates the activity of a protein of interest; and b) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide is preferably selected by phage display, E. coli display, ribosome display, RNA-peptide screening, or chemical-peptide screening.

10. 发明申请

US20050080014A1 Thrombopoietic compounds 有权
标题翻译：血栓形成
公开(公告)号：US20050080014A1
公开(公告)日：2005-04-14
申请号：US10933133
申请日：2004-09-02
申请人： Chuan-Fa Liu , Ulrich Feige , Janet Cheetham
发明人： Chuan-Fa Liu , Ulrich Feige , Janet Cheetham
IPC分类号： C12N15/09 , A61K38/00 , A61P7/00 , C07K14/52 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12P21/02 , A61K38/08 , C07K7/08
CPC分类号： C07K14/524 , A61K38/00 , C07K7/06 , C07K7/08 , C07K2319/00 , C07K2319/30 , C07K2319/75
摘要： The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.
摘要翻译：本发明涉及具有血小板生成活性的化合物，特别是肽或多肽的领域。本发明的肽和多肽可用于增加哺乳动物中的血小板或血小板前体（例如巨核细胞）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式